The present invention relates to a novel process for the preparation of 1ß-methylcarbapenem antibiotic, Ertapenem of formula I. The process comprises isolation of monoprotected Ertapenem acid or its monosodium salt and further deprotection to obtain Ertapenenm monosodium.
The present invention relates to a novel cost effective and commercially viable process for the preparation of pure crystalline Imipenem monohydrate by dissolving crude imipenem in carbonated water and morpholinopropane sulphonic acid (MOPS); treating with carbon, filering and precipitating by an organic solvent.
...
The present invention relates to a novel process for the preparation of cilastatin of formula I by the condensation of 7-chloro-2-[[(1S)-2,2-dimethylcyclopropane] carboxamide]-2-heptenoic acid with L-cysteine in presence of l,8-diazabicyclo[4.3.0]undec-7-ene (DBU) and a solvent.
FIG
Documents
Form STK-2-26072019-signed
Form ADT-1-21062019_signed
Copy of written consent given by auditor-30052019
Copy of resolution passed by the company-30052019
-10012019
Optional Attachment-(1)-10012019
Form MGT-14-09012019_signed
Copy(s) of resolution(s) along with copy of explanatory statement under section 173-09012019
Optional Attachment-(1)-09012019
Form MGT-7-28112018_signed
List of share holders, debenture holders;-27112018
XBRL financial statements duly authenticated as per section 134 (including Board's report,auditor's report and other documents)-24102018